image credit: Freepik

GSK’s five-in-one meningococcal vaccine candidate shows promise in phase 3 trial

May 15, 2023


Preliminary results for the MenABCWY candidate were presented by the company at the European Society for Paediatric Infectious Diseases congress in Lisbon, Portugal.

Invasive meningococcal disease (IMD) is an uncommon but serious illness that can cause life-threatening complications or even death, with the highest incidence occurring in children and adolescents.

Five Neisseria meningitides serogroups – A, B, C, W, and Y – account for nearly all IMD cases, but there are currently no approved vaccines that offer simultaneous protection against all of them.

Read More on PMLiVE